Eisai’s Lecanemab: US FDA Showed Flexibility On Clinical Endpoint Results, Safety Database Size

Alzheimer’s drug’s failure to meet Phase II endpoint did not preclude accelerated approval in light of statistically significant reduction in amyloid plaque and ‘generally consistent and favorable results on clinical endpoints.’ Size of six-month safety database also fell shy of ICH guidelines.

Slinky
FDA showed some flexibility on data requirements for lecanemab given the serious nature of Alzheimer's disease. • Source: Shutterstock

The US FDA exercised regulatory flexibility on Eisai Co., Ltd. and Biogen, Inc.’s Leqembi (lecanemab-irmb) in its evaluation of clinical efficacy data, and the size of the safety database, for the Alzheimer’s disease drug.

The drug failed to meet the prespecified clinical endpoint in a Phase II trial. However, since it was following the...

More from Approvals

More from Product Reviews

‘Missed Opportunity’: GSK Failed To Optimize Blenrep Dosage, US FDA Panel Says

 
• By 

The Oncologic Drugs Advisory Committee said the benefit-risk of belantamab mafoditin for two second-line multiple myeloma indications is not favorable at the proposed dosages and raised concerns about applicability of trial results to US patients.

‘Unprecedented Story’: Revoked EU Marketing Authorization Fails To Thwart Translarna Sales

 

PTC Therapeutics is continuing to supply its Duchenne muscular dystrophy treatment, Translarna, in some European markets, despite EU revocation of the drug’s conditional marketing authorization earlier this year.

US FDA’s Second Half 2025 User Fee Goals Swing Toward Respiratory Disease

 

The 43 novel agents with user fee goal dates in the remainder of 2025 have fewer oncologics and infectious disease drugs than the first half of the year.